Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11
Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11
瑞昱與賽諾菲安萬特的Dupixent獲得歐盟批准，可用於1至11歲兒童患有嗜酸性食道炎，爲他們帶來新希望
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year
批准基於第三階段的數據，該數據顯示，服用Dupixent的兒童在16周時實現組織學疾病緩解的人數明顯多於安慰劑，後者持續長達一年
Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial
Dupixent是歐盟有史以來第一種用於治療這些年輕患者的藥物，這些患者在人生的關鍵階段一直難以進食，而生長至關重要
資訊熱榜
更新時間